Format

Send to

Choose Destination
Vaccine. 2017 Jun 8;35(26):3395-3400. doi: 10.1016/j.vaccine.2017.05.008. Epub 2017 May 12.

Waning protection following 5 doses of a 3-component diphtheria, tetanus, and acellular pertussis vaccine.

Author information

1
Kaiser Permanente Vaccine Study Center, 1 Kaiser Plaza, 16(th) Floor, Oakland, CA 94612, United States. Electronic address: Nicola.Klein@kp.org.
2
Kaiser Permanente Vaccine Study Center, 1 Kaiser Plaza, 16(th) Floor, Oakland, CA 94612, United States. Electronic address: Joan.Bartlett@kp.org.
3
Kaiser Permanente Vaccine Study Center, 1 Kaiser Plaza, 16(th) Floor, Oakland, CA 94612, United States. Electronic address: Bruce.Fireman@kp.org.
4
Kaiser Permanente Vaccine Study Center, 1 Kaiser Plaza, 16(th) Floor, Oakland, CA 94612, United States. Electronic address: Laurie.A.Aukes@kp.org.
5
GSK, US Health Outcomes & Epidemiology - Vaccines, 5 Crescent Drive, Philadelphia, PA 19112, United States. Electronic address: philip.o.buck@gsk.com.
6
GSK, US Health Outcomes & Epidemiology - Vaccines, 5 Crescent Drive, Philadelphia, PA 19112, United States. Electronic address: shanthy76@hotmail.com.
7
Kaiser Permanente Vaccine Study Center, 1 Kaiser Plaza, 16(th) Floor, Oakland, CA 94612, United States.

Abstract

BACKGROUND:

The effectiveness of diphtheria, tetanus, and acellular pertussis (DTaP) vaccines wanes substantially after the 5th dose given at ages 4-6years, but has not been described following 5 doses of the same type of DTaP vaccine. We investigated waning effectiveness against pertussis in California over nearly 10years, which included large pertussis outbreaks, following 5 doses of GSK DTaP vaccines (DTaP3).

METHODS:

We conducted a case-control study (NCT02447978) of children who received 5 doses of DTaP at Kaiser Permanente Northern California from 01/2006 through 03/2015. We compared time since the 5th dose in confirmed pertussis polymerase chain reaction (PCR)-positive cases with pertussis PCR-negative controls. We used logistic regression adjusted for calendar time, age, sex, race, and service area to estimate the effect of time since the 5th DTaP dose on the odds of pertussis. Our primary analysis evaluated waning after 5 doses of DTaP3. We also examined waning after 5 doses of any type of DTaP vaccines.

RESULTS:

Our primary analysis compared 340 pertussis cases diagnosed at ages 4-12years with 3841 controls. The any DTaP analysis compared 462 pertussis cases with 5649 controls. The majority of all DTaP doses in the study population were DTaP3 (86.8%). Children who were more remote from their 5th dose were less protected than were children whose 5th dose was more recent; the adjusted odds of pertussis increased by 1.27 per year (95% CI 1.10, 1.46) after 5 doses of DTaP3 and by 1.30 per year (95% CI 1.15, 1.46) after any 5 DTaP vaccines doses.

CONCLUSIONS:

Waning protection after DTaP3 was similar to that following 5 doses of any type of DTaP vaccines. This finding is not unexpected as most of the DTaP vaccines administered were DTaP3. Following 5 doses of DTaP3 vaccines, protection from pertussis waned 27% per year on average. NCT number: NCT02447978.

KEYWORDS:

Pertussis; Protection; Vaccine; Waning

PMID:
28506516
DOI:
10.1016/j.vaccine.2017.05.008
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center